# A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases

> **NCT04299646** · PHASE2 · RECRUITING · sponsor: **Centre Francois Baclesse** · enrollment: 77 (estimated)

## Conditions studied

- Metastatic Renal Cell Carcinoma
- Radiotherapy

## Interventions

- **RADIATION:** Steretactic radiotherapy

## Key facts

- **NCT ID:** NCT04299646
- **Lead sponsor:** Centre Francois Baclesse
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-01
- **Primary completion:** 2027-04
- **Final completion:** 2029-08
- **Target enrollment:** 77 (ESTIMATED)
- **Last updated:** 2026-01-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04299646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04299646, "A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04299646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*